Aclaris Therapeutics, Inc.
ACRSAclaris Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing immuno-oncology and dermatology therapies. Founded in 2012 and headquartered in Wayne, Pennsylvania, the company is known for its focus on immune-mediated diseases and dermatological conditions, leveraging innovative small molecule and antibody-based approaches.
Company News
Aclaris Therapeutics announced that results from its Phase 2a trial of ATI-2138, an investigational oral covalent inhibitor of ITK and JAK3, will be presented as an ePoster at the 2026 AAD Annual Meeting in Denver. The poster will include previously unreported results from the open-label trial in patients with moderate-to-severe atopic dermatitis.
Aclaris Therapeutics announced the initiation of a Phase 1b proof-of-concept trial for ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, in asthma patients. This follows the recent start of a similar trial in atopic dermatitis. The company expects to report top-line results from both trials in the second half of 2026 and plans to initiat...
Aclaris Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City on December 2, 2025, with CEO Dr. Neal Walker presenting a fireside chat.
Aclaris Therapeutics will present additional results from its Phase 2a trial of ATI-2138, an investigational oral drug targeting ITK and JAK3, at the 2025 European Academy of Dermatology and Venereology Congress in Paris.
Aclaris Therapeutics will participate in two healthcare conferences in September 2025, with CEO Dr. Neal Walker presenting at the Cantor Global Healthcare Conference and H.C. Wainwright Global Investment Conference.
